Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Potent non-peptide thrombin receptor antagonists.

Samuel Chackalamannil1, Ho-Sam Ahn, Yan Xia

  • 1Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. samuel.chackalamannil@spcorp.com

Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|August 20, 2004
PubMed
Summary

New low molecular weight antagonists targeting Protease Activated Receptor-1 (PAR-1) show promise for treating thrombotic and vascular disorders. These compounds effectively inhibit thrombin-induced cellular activation, offering a potential therapeutic strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short form scale of parent self-efficacy for general and specialized care for children with special health care needs.

Journal of patient-reported outcomes·2026
Same author

Forgone Family Employment and Care Coordination in Children With Medical Complexity.

Hospital pediatrics·2026
Same author

Complex Needs, Complex Costs: Assessing Medicaid payments on a subset of home- and community-based services for children by level of complexity in South Carolina.

Academic pediatrics·2026
Same author

Evaluating Predictors of Family Caregiver's Self-Efficacy Managing Their Children's Health Care.

Hospital pediatrics·2026
Same author

Use of Emergency Medical Services for Children With Medical Complexity.

Pediatrics·2026
Same author

Medical Device Design Flaws for Children With Medical Complexity at Home.

Pediatrics·2026

Area of Science:

  • Pharmacology
  • Cardiovascular Biology
  • Molecular Medicine

Background:

  • Protease Activated Receptor-1 (PAR-1), or thrombin receptor, mediates cellular activation in platelets and endothelial cells.
  • Thrombin-induced PAR-1 activation is implicated in thrombotic and vascular proliferative disorders like atherosclerosis and restenosis.
  • Inhibiting PAR-1 offers a potential therapeutic avenue for these conditions.

Purpose of the Study:

  • To report the pharmacology of novel, potent, low molecular weight antagonists targeting PAR-1.
  • To evaluate the efficacy of these antagonists in inhibiting thrombin-mediated cellular signaling and platelet activation.
  • To explore potential therapeutic applications in vascular proliferative disorders.

Main Methods:

  • Radioligand binding assays to assess competitive inhibition of PAR-1.

Related Experiment Videos

  • Inhibition assays for thrombin and agonist peptide-induced human platelet aggregation.
  • Measurement of agonist-induced cytosolic Ca(+2) transients and thymidine incorporation in human coronary artery smooth muscle cells (hCASMC).

    • Main Results:

    • Compounds from pyrroloquinazoline, benzimidazole, and himbacine series demonstrated potent, competitive inhibition of PAR-1.
    • These antagonists dose-dependently inhibited human platelet aggregation induced by thrombin and agonist peptides.
    • Inhibition of Ca(+2) transients and thymidine incorporation in hCASMC was also observed in a dose-dependent manner.
    • The most potent antagonist exhibited a Ki of 12 nM and an IC50 of 70 nM in binding and platelet aggregation assays, respectively.

    Conclusions:

    • Novel low molecular weight PAR-1 antagonists display significant pharmacological activity.
    • These compounds effectively inhibit key pathways involved in thrombin-mediated cellular activation.
    • The findings support the potential of these antagonists as therapeutic agents for thrombotic and vascular proliferative diseases.